How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Buy
61
ALDX Quote, Financials, Valuation and Earnings
Last price:
$5.34
Seasonality move
:
-4.43%
Day range:
$5.37 - $5.55
52-week range:
$1.14 - $7.20
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
6.62x
Volume:
595.9K
Avg. volume:
1.2M
1-year change:
3.63%
Market cap:
$326.1M
Revenue:
--
EPS (TTM):
-$0.72
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ALDX
Aldeyra Therapeutics, Inc.
|
$24.3M | -$0.15 | -- | -44.74% | $9.67 |
|
AGIO
Agios Pharmaceuticals, Inc.
|
$12.1M | -$1.95 | 80.51% | -19.53% | $36.75 |
|
ALT
Altimmune, Inc.
|
$560 | -$0.24 | -85.8% | -1.45% | $17.38 |
|
ATNM
Actinium Pharmaceuticals, Inc.
|
-- | -$0.19 | -100% | -12.44% | $5.00 |
|
MNOV
MediciNova, Inc.
|
-- | -$0.12 | -100% | -109.06% | $10.00 |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$59.3M | -- | 23.5% | -- | $13.63 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ALDX
Aldeyra Therapeutics, Inc.
|
$5.42 | $9.67 | $326.1M | -- | $0.00 | 0% | -- |
|
AGIO
Agios Pharmaceuticals, Inc.
|
$28.31 | $36.75 | $1.7B | 3.91x | $0.00 | 0% | 36.45x |
|
ALT
Altimmune, Inc.
|
$5.12 | $17.38 | $533.7M | -- | $0.00 | 0% | 20,313.21x |
|
ATNM
Actinium Pharmaceuticals, Inc.
|
$1.22 | $5.00 | $38.1M | -- | $0.00 | 0% | 422.88x |
|
MNOV
MediciNova, Inc.
|
$1.79 | $10.00 | $88M | -- | $0.00 | 0% | 340.41x |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$7.69 | $13.63 | $454.5M | -- | $0.00 | 0% | 2.13x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ALDX
Aldeyra Therapeutics, Inc.
|
23.99% | 2.161 | 4.95% | 2.64x |
|
AGIO
Agios Pharmaceuticals, Inc.
|
3.35% | 2.263 | 1.9% | 12.81x |
|
ALT
Altimmune, Inc.
|
7.89% | 0.672 | 4.41% | 16.79x |
|
ATNM
Actinium Pharmaceuticals, Inc.
|
7.66% | -2.827 | 2.29% | 7.81x |
|
MNOV
MediciNova, Inc.
|
0.58% | 0.858 | 0.41% | 9.76x |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
2.29% | -0.960 | 3.7% | 2.92x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ALDX
Aldeyra Therapeutics, Inc.
|
-$63.7K | -$8M | -53.75% | -66.61% | -- | -$7M |
|
AGIO
Agios Pharmaceuticals, Inc.
|
$9.8M | -$116.9M | -26.57% | -27.53% | -907.37% | -$89.7M |
|
ALT
Altimmune, Inc.
|
-$22K | -$20.9M | -53.6% | -56.24% | -417180% | -$11.9M |
|
ATNM
Actinium Pharmaceuticals, Inc.
|
-$116K | -$5.7M | -126.64% | -133.63% | -6324.44% | -$6.3M |
|
MNOV
MediciNova, Inc.
|
-$39K | -$3.4M | -24.01% | -24.18% | -2742.09% | -$1.7M |
|
VNDA
Vanda Pharmaceuticals, Inc.
|
$51.6M | -$31.3M | -16.2% | -16.55% | -55.61% | -$31.8M |
Aldeyra Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns ALDX or AGIO?
Agios Pharmaceuticals, Inc. has a net margin of -- compared to Aldeyra Therapeutics, Inc.'s net margin of -803.05%. Aldeyra Therapeutics, Inc.'s return on equity of -66.61% beat Agios Pharmaceuticals, Inc.'s return on equity of -27.53%.
Company Gross Margin Earnings Per Share Invested Capital ALDXAldeyra Therapeutics, Inc.-- -$0.13 $64.8M AGIOAgios Pharmaceuticals, Inc.76.3% -$1.78 $1.3B -
What do Analysts Say About ALDX or AGIO?
Aldeyra Therapeutics, Inc. has a consensus price target of $9.67, signalling upside risk potential of 78.35%. On the other hand Agios Pharmaceuticals, Inc. has an analysts' consensus of $36.75 which suggests that it could grow by 29.81%. Given that Aldeyra Therapeutics, Inc. has higher upside potential than Agios Pharmaceuticals, Inc., analysts believe Aldeyra Therapeutics, Inc. is more attractive than Agios Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ALDXAldeyra Therapeutics, Inc.4 0 0 AGIOAgios Pharmaceuticals, Inc.7 3 0 -
Is ALDX or AGIO More Risky?
Aldeyra Therapeutics, Inc. has a beta of 0.858, which suggesting that the stock is 14.241% less volatile than S&P 500. In comparison Agios Pharmaceuticals, Inc. has a beta of 0.894, suggesting its less volatile than the S&P 500 by 10.585%.
-
Which is a Better Dividend Stock ALDX or AGIO?
Aldeyra Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agios Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aldeyra Therapeutics, Inc. pays -- of its earnings as a dividend. Agios Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ALDX or AGIO?
Aldeyra Therapeutics, Inc. quarterly revenues are --, which are smaller than Agios Pharmaceuticals, Inc. quarterly revenues of $12.9M. Aldeyra Therapeutics, Inc.'s net income of -$7.7M is higher than Agios Pharmaceuticals, Inc.'s net income of -$103.4M. Notably, Aldeyra Therapeutics, Inc.'s price-to-earnings ratio is -- while Agios Pharmaceuticals, Inc.'s PE ratio is 3.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aldeyra Therapeutics, Inc. is -- versus 36.45x for Agios Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALDXAldeyra Therapeutics, Inc.-- -- -- -$7.7M AGIOAgios Pharmaceuticals, Inc.36.45x 3.91x $12.9M -$103.4M
-
Which has Higher Returns ALDX or ALT?
Altimmune, Inc. has a net margin of -- compared to Aldeyra Therapeutics, Inc.'s net margin of -380280%. Aldeyra Therapeutics, Inc.'s return on equity of -66.61% beat Altimmune, Inc.'s return on equity of -56.24%.
Company Gross Margin Earnings Per Share Invested Capital ALDXAldeyra Therapeutics, Inc.-- -$0.13 $64.8M ALTAltimmune, Inc.-440% -$0.21 $201.5M -
What do Analysts Say About ALDX or ALT?
Aldeyra Therapeutics, Inc. has a consensus price target of $9.67, signalling upside risk potential of 78.35%. On the other hand Altimmune, Inc. has an analysts' consensus of $17.38 which suggests that it could grow by 187.22%. Given that Altimmune, Inc. has higher upside potential than Aldeyra Therapeutics, Inc., analysts believe Altimmune, Inc. is more attractive than Aldeyra Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ALDXAldeyra Therapeutics, Inc.4 0 0 ALTAltimmune, Inc.5 1 1 -
Is ALDX or ALT More Risky?
Aldeyra Therapeutics, Inc. has a beta of 0.858, which suggesting that the stock is 14.241% less volatile than S&P 500. In comparison Altimmune, Inc. has a beta of 0.037, suggesting its less volatile than the S&P 500 by 96.298%.
-
Which is a Better Dividend Stock ALDX or ALT?
Aldeyra Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Altimmune, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aldeyra Therapeutics, Inc. pays -- of its earnings as a dividend. Altimmune, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ALDX or ALT?
Aldeyra Therapeutics, Inc. quarterly revenues are --, which are smaller than Altimmune, Inc. quarterly revenues of $5K. Aldeyra Therapeutics, Inc.'s net income of -$7.7M is higher than Altimmune, Inc.'s net income of -$19M. Notably, Aldeyra Therapeutics, Inc.'s price-to-earnings ratio is -- while Altimmune, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aldeyra Therapeutics, Inc. is -- versus 20,313.21x for Altimmune, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALDXAldeyra Therapeutics, Inc.-- -- -- -$7.7M ALTAltimmune, Inc.20,313.21x -- $5K -$19M
-
Which has Higher Returns ALDX or ATNM?
Actinium Pharmaceuticals, Inc. has a net margin of -- compared to Aldeyra Therapeutics, Inc.'s net margin of -5701.11%. Aldeyra Therapeutics, Inc.'s return on equity of -66.61% beat Actinium Pharmaceuticals, Inc.'s return on equity of -133.63%.
Company Gross Margin Earnings Per Share Invested Capital ALDXAldeyra Therapeutics, Inc.-- -$0.13 $64.8M ATNMActinium Pharmaceuticals, Inc.-128.89% -$0.16 $14.9M -
What do Analysts Say About ALDX or ATNM?
Aldeyra Therapeutics, Inc. has a consensus price target of $9.67, signalling upside risk potential of 78.35%. On the other hand Actinium Pharmaceuticals, Inc. has an analysts' consensus of $5.00 which suggests that it could grow by 309.84%. Given that Actinium Pharmaceuticals, Inc. has higher upside potential than Aldeyra Therapeutics, Inc., analysts believe Actinium Pharmaceuticals, Inc. is more attractive than Aldeyra Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ALDXAldeyra Therapeutics, Inc.4 0 0 ATNMActinium Pharmaceuticals, Inc.3 1 0 -
Is ALDX or ATNM More Risky?
Aldeyra Therapeutics, Inc. has a beta of 0.858, which suggesting that the stock is 14.241% less volatile than S&P 500. In comparison Actinium Pharmaceuticals, Inc. has a beta of -0.303, suggesting its less volatile than the S&P 500 by 130.258%.
-
Which is a Better Dividend Stock ALDX or ATNM?
Aldeyra Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Actinium Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aldeyra Therapeutics, Inc. pays -- of its earnings as a dividend. Actinium Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ALDX or ATNM?
Aldeyra Therapeutics, Inc. quarterly revenues are --, which are smaller than Actinium Pharmaceuticals, Inc. quarterly revenues of $90K. Aldeyra Therapeutics, Inc.'s net income of -$7.7M is lower than Actinium Pharmaceuticals, Inc.'s net income of -$5.1M. Notably, Aldeyra Therapeutics, Inc.'s price-to-earnings ratio is -- while Actinium Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aldeyra Therapeutics, Inc. is -- versus 422.88x for Actinium Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALDXAldeyra Therapeutics, Inc.-- -- -- -$7.7M ATNMActinium Pharmaceuticals, Inc.422.88x -- $90K -$5.1M
-
Which has Higher Returns ALDX or MNOV?
MediciNova, Inc. has a net margin of -- compared to Aldeyra Therapeutics, Inc.'s net margin of -2473.97%. Aldeyra Therapeutics, Inc.'s return on equity of -66.61% beat MediciNova, Inc.'s return on equity of -24.18%.
Company Gross Margin Earnings Per Share Invested Capital ALDXAldeyra Therapeutics, Inc.-- -$0.13 $64.8M MNOVMediciNova, Inc.-31.63% -$0.06 $44.2M -
What do Analysts Say About ALDX or MNOV?
Aldeyra Therapeutics, Inc. has a consensus price target of $9.67, signalling upside risk potential of 78.35%. On the other hand MediciNova, Inc. has an analysts' consensus of $10.00 which suggests that it could grow by 458.66%. Given that MediciNova, Inc. has higher upside potential than Aldeyra Therapeutics, Inc., analysts believe MediciNova, Inc. is more attractive than Aldeyra Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ALDXAldeyra Therapeutics, Inc.4 0 0 MNOVMediciNova, Inc.2 0 0 -
Is ALDX or MNOV More Risky?
Aldeyra Therapeutics, Inc. has a beta of 0.858, which suggesting that the stock is 14.241% less volatile than S&P 500. In comparison MediciNova, Inc. has a beta of 0.517, suggesting its less volatile than the S&P 500 by 48.324%.
-
Which is a Better Dividend Stock ALDX or MNOV?
Aldeyra Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MediciNova, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aldeyra Therapeutics, Inc. pays -- of its earnings as a dividend. MediciNova, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ALDX or MNOV?
Aldeyra Therapeutics, Inc. quarterly revenues are --, which are smaller than MediciNova, Inc. quarterly revenues of $123.3K. Aldeyra Therapeutics, Inc.'s net income of -$7.7M is lower than MediciNova, Inc.'s net income of -$3.1M. Notably, Aldeyra Therapeutics, Inc.'s price-to-earnings ratio is -- while MediciNova, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aldeyra Therapeutics, Inc. is -- versus 340.41x for MediciNova, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALDXAldeyra Therapeutics, Inc.-- -- -- -$7.7M MNOVMediciNova, Inc.340.41x -- $123.3K -$3.1M
-
Which has Higher Returns ALDX or VNDA?
Vanda Pharmaceuticals, Inc. has a net margin of -- compared to Aldeyra Therapeutics, Inc.'s net margin of -40.15%. Aldeyra Therapeutics, Inc.'s return on equity of -66.61% beat Vanda Pharmaceuticals, Inc.'s return on equity of -16.55%.
Company Gross Margin Earnings Per Share Invested Capital ALDXAldeyra Therapeutics, Inc.-- -$0.13 $64.8M VNDAVanda Pharmaceuticals, Inc.91.64% -$0.38 $476.9M -
What do Analysts Say About ALDX or VNDA?
Aldeyra Therapeutics, Inc. has a consensus price target of $9.67, signalling upside risk potential of 78.35%. On the other hand Vanda Pharmaceuticals, Inc. has an analysts' consensus of $13.63 which suggests that it could grow by 77.18%. Given that Aldeyra Therapeutics, Inc. has higher upside potential than Vanda Pharmaceuticals, Inc., analysts believe Aldeyra Therapeutics, Inc. is more attractive than Vanda Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ALDXAldeyra Therapeutics, Inc.4 0 0 VNDAVanda Pharmaceuticals, Inc.3 1 0 -
Is ALDX or VNDA More Risky?
Aldeyra Therapeutics, Inc. has a beta of 0.858, which suggesting that the stock is 14.241% less volatile than S&P 500. In comparison Vanda Pharmaceuticals, Inc. has a beta of 0.604, suggesting its less volatile than the S&P 500 by 39.647%.
-
Which is a Better Dividend Stock ALDX or VNDA?
Aldeyra Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aldeyra Therapeutics, Inc. pays -- of its earnings as a dividend. Vanda Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ALDX or VNDA?
Aldeyra Therapeutics, Inc. quarterly revenues are --, which are smaller than Vanda Pharmaceuticals, Inc. quarterly revenues of $56.3M. Aldeyra Therapeutics, Inc.'s net income of -$7.7M is higher than Vanda Pharmaceuticals, Inc.'s net income of -$22.6M. Notably, Aldeyra Therapeutics, Inc.'s price-to-earnings ratio is -- while Vanda Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aldeyra Therapeutics, Inc. is -- versus 2.13x for Vanda Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ALDXAldeyra Therapeutics, Inc.-- -- -- -$7.7M VNDAVanda Pharmaceuticals, Inc.2.13x -- $56.3M -$22.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.7T
P/E Ratio: 65x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Sell
48
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Buy
72
BNAI alert for Jan 29
Brand Engagement Network, Inc. [BNAI] is down 16.89% over the past day.
Buy
82
STX alert for Jan 29
Seagate Technology Holdings Plc [STX] is up 0.83% over the past day.
Buy
84
GDXU alert for Jan 29
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 12.19% over the past day.
